Literature DB >> 10423121

1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization.

J Chalmers1, S MacMahon, G Mancia, J Whitworth, L Beilin, L Hansson, B Neal, A Rodgers, C Ni Mhurchu, T Clark.   

Abstract

The present Guidelines were prepared by the Guidelines Sub-Committee of the World Health Organization-International Society of Hypertension (WHO-ISH) Mild Hypertension Liaison Committee, the members of which are listed at the end of the text. These guidelines represent the fourth revision of the WHO-ISH Guidelines and were finalised after presentation and discussion at the 7th WHO-ISH Meeting on Hypertension, Fukuoka, Japan, 29th Sept-1st Oct, 1998. Previous versions of the Guidelines were published in Bull WHO 1993, 71:503-517 and J Hypertens 1993, 11:905-918.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10423121     DOI: 10.3109/10641969909061028

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  181 in total

Review 1.  What is the optimal strategy to intensify blood pressure control and prevent progression of renal failure?

Authors:  M Epstein; S Tobe
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

Review 2.  Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines.

Authors:  William H Frishman; Mamata Alwarshetty
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Cardiovascular risk management of hypertension and hypercholesterolaemia in the Netherlands: from unifactorial to multifactorial approach.

Authors:  I van Dis; J M Geleijnse; W M M Verschuren; D Kromhout
Journal:  Neth Heart J       Date:  2012-08       Impact factor: 2.380

4.  Association of two polymorphisms in the FADS1/FADS2 gene cluster and the risk of coronary artery disease and ischemic stroke.

Authors:  Qian Yang; Rui-Xing Yin; Xiao-Li Cao; Dong-Feng Wu; Wu-Xian Chen; Yi-Jiang Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

5.  VKORC1 and CD-14 genetic polymorphisms associate with susceptibility to cardiovascular and cerebrovascular diseases.

Authors:  Jian Du; Zhiguo Zhang; Yuanyuan Ge; Juan Zhen; Jiyan Leng; Jianmeng Wang
Journal:  Int J Clin Exp Med       Date:  2015-11-15

6.  Effects of antihypertensive treatments on incidence of diabetes: a case-control study.

Authors:  M Monami; A Ungar; C Lamanna; G Bardini; L Pala; I Dicembrini; C Marchi; M Vivarelli; S Zannoni; N Bartoli; N Marchionni; C M Rotella; E Mannucci
Journal:  J Endocrinol Invest       Date:  2011-05-24       Impact factor: 4.256

7.  Blood Pressure Variability, Mortality, and Cardiovascular Outcomes in CKD Patients.

Authors:  Francesca Mallamaci; Giovanni Tripepi; Graziella D'Arrigo; Silvio Borrelli; Carlo Garofalo; Giovanna Stanzione; Michele Provenzano; Luca De Nicola; Giuseppe Conte; Roberto Minutolo; Carmine Zoccali
Journal:  Clin J Am Soc Nephrol       Date:  2019-01-02       Impact factor: 8.237

8.  The Morbidity and Comorbidity of Nonalcoholic Fatty Liver Disease and Different Glucose Intolerance Strata in a Community-Based Chinese Population.

Authors:  Xiuying Zhang; Xianghai Zhou; Xueyao Han; Zuodi Fu; Lianying Wang; Yufeng Li; Linong Ji
Journal:  Metab Syndr Relat Disord       Date:  2020-05-27       Impact factor: 1.894

9.  Contribution of ENPP1, TCF7L2, and FTO polymorphisms to type 2 diabetes in mixed ancestry ethnic population of South Africa.

Authors:  Yandiswa Y Yako; Jabulisile H Madubedube; Andre P Kengne; Rajiv T Erasmus; Tahir S Pillay; Tandi E Matsha
Journal:  Afr Health Sci       Date:  2015-12       Impact factor: 0.927

10.  The effect of telmisartan on endothelial function and arterial stiffness in patients with essential hypertension.

Authors:  An Doc Jung; Weon Kim; Sang Hyun Park; Jeong Su Park; Sang Cheol Cho; Sung Bum Hong; Sun Ho Hwang; Wan Kim
Journal:  Korean Circ J       Date:  2009-05-28       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.